Urologic Chronic Pelvic Pain Syndrome

Martínez-Bianchi, Viviana; Halstater, BH

doi:10.1016/j.pop.2010.05.002

Cited by 6 publications

(5 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At present, there is no known etiology nor treatments that can effectively diminish or abolish the symptoms. The diagnosis of BPS/IC is based on symptom criteria which include suprapubic pain associated with bladder filling often accompanied by a strong desire to void and increased frequency of urination (52,62,200). In addition, overlapping or chronic conditions (such as OAB) often share a number of similar features (such as urgency and suprapubic pressure) (195).…”

Section: A Bladder Pain Syndromementioning

confidence: 99%

Urothelial Signaling

Birder

Andersson

2013

Physiological Reviews

399

362

View full text Add to dashboard Cite

The urothelium, which lines the inner surface of the renal pelvis, the ureters, and the urinary bladder, not only forms a high-resistance barrier to ion, solute and water flux, and pathogens, but also functions as an integral part of a sensory web which receives, amplifies, and transmits information about its external milieu. Urothelial cells have the ability to sense changes in their extracellular environment, and respond to chemical, mechanical and thermal stimuli by releasing various factors such as ATP, nitric oxide, and acetylcholine. They express a variety of receptors and ion channels, including P2X3 purinergic receptors, nicotinic and muscarinic receptors, and TRP channels, which all have been implicated in urothelial-neuronal interactions, and involved in signals that via components in the underlying lamina propria, such as interstitial cells, can be amplified and conveyed to nerves, detrusor muscle cells, and ultimately the central nervous system. The specialized anatomy of the urothelium and underlying structures, and the possible communication mechanisms from urothelial cells to various cell types within the bladder wall are described. Changes in the urothelium/ lamina propria ("mucosa") produced by different bladder disorders are discussed, as well as the mucosa as a target for therapeutic interventions.

show abstract

Section: A Bladder Pain Syndromementioning

confidence: 99%

Urothelial Signaling

Birder

Andersson

2013

Physiological Reviews

399

362

View full text Add to dashboard Cite

show abstract

“…17 Because IC/PBS patients have genital and pelvic pain often linked to sexual and urinary symptoms, but no history of recognized UTI. 23…”

Section: Categorization Of Prostatitismentioning

confidence: 99%

“…84 Similarly, pregabalin is also considered for its efficacy in UCPPS patients. 23 Likewise, 324 males, 218 of whom were randomized to either placebo or pregabalin, established that enhancements in CPSI and global pain scores. 85 In all men, a 6-point decrease in CPSI scores while this was not statistically significant.…”

Section: Treatment Optionsmentioning

confidence: 99%

Therapeutic interventions to urologic chronic pelvic pain syndrome and UPOINT system for clinical phenotyping: How far are we?

Naveed

Ihsan

et al. 2022

Urologia

View full text Add to dashboard Cite

The assessment and management of urologic chronic pelvic pain syndrome (UCPPS), is controversial. It is classified by voiding symptoms, pelvic pain, and bladder pain, which is weekly treated, weekly understood, and bothersome. In the aspect of clinical efforts and research to help people with this syndrome have been hampered by the deficiency of a widely reliable, accepted, and a valuable tool to evaluate the patient symptoms and quality of life (QoL) impact. However, the etiology comes into sight is multifactorial, and available treatment options have been imprecise considerably in present years. We compiled the published literature on the assessment of the syndrome, a tentative role of pharmacological and non-pharmacological (conservative, alternative, and invasive therapy) interventions in eradicating the disease as well as improving symptoms. The previously published literature on animal models has established the association of immune systems in the etiology, pathogenesis, and progression of the disease. The UPOINT system for clinical phenotyping of UCPPS patients has six predefined domains that direct multimodal therapy, which would lead to significant symptom improvement in the medical field. The narrative review aims to scrutinize the fluctuating scientist’s views on the evaluation of patient and multimodal treatment of the UPOINT system.

show abstract

“…There is no generally agreed upon etiology or pathophysiology for these syndromes, and no effective treatments able to eradicate the symptoms in humans. This condition is characterized by suprapubic pain, associated with bladder filling and can also be accompanied by a persistent strong desire to void, increased frequency of urination and nocturia 1–6. The presence of non‐painful symptoms such as urgency and suprapubic pressure suggests overlap with OAB 14…”

Section: Cystitis and Animal Modelsmentioning

confidence: 99%

“…Interstitial cystitis (painful bladder syndrome/interstitial cystitis; PBS/IC) is a persistent pain syndrome affecting the urinary bladder with symptoms including urinary frequency, bladder pain, and nocturia 1–6. Various animal models have been studied, most of which mimic some aspect of the human condition of interest to the investigator(s).…”

Section: Introductionmentioning

confidence: 99%

Cystitis, Co‐morbid disorders and associated epithelial dysfunction

Birder

Hanna-Mitchell

Mayer

et al. 2011

Neurourology and Urodynamics

View full text Add to dashboard Cite

Introduction Interstitial cystitis (painful bladder syndrome / interstitial cystitis; PBS/IC) is a persistent pain syndrome affecting the urinary bladder with symptoms including urinary frequency, bladder pain and nocturia.(1–6) Various animal models have been studied, most of which mimic some aspect of the human condition of interest to the investigator(s). This review will provide examples of various animal models including those incorporating chronic stress, thought to produce features that share similarities to that of PBS/IC patients, whose symptoms are often exacerbated by various stressors. (7–12) This review also provides evidence that patients with PBS/IC exhibit abnormalities within the bladder epithelium (or urothelium), even though a consistent relationship of such changes with symptom severity has not been demonstrated. These changes include alterations in urothelial integrity, differentiation and/or proliferation as well as changes in ‘sensory’ function (altered expression or sensitivity of receptors and ion channels). Establishing a diagnostic ‘indicator’ with a high degree of correlation in this syndrome would be of value in terms of disease status, diagnosis and treatment. There have been reports of a number of factors/mediators altered in PBS/IC. However, the lack of a validated biomarker and a well-defined etiology for this syndrome introduces a number of complications, including diagnostic confidence, choice of appropriate animal models to study basic mechanism with the goal toward treatment, and rational therapies. It is also becoming increasingly apparent that patients with PBS/IC often overlap or share symptoms commonly associated with other persistent pain disorders. These include (but are not limited to) irritable bowel syndrome (IBS), non-cardiac chest pain, fibromyalgia and even overactive bladder syndrome (OAB).(13–18) Such types of changes are not limited to the urinary bladder, however, as reports of alterations in epithelial signaling/barrier function have been described in patients diagnosed with a wider variety of syndromes, including functional and inflammatory bowel disorders such as irritable bowel syndrome (IBS), gastrointestinal esophageal reflux disease (GERD) and asthma.(19–21) These and other findings suggest that changes within the epithelium (barrier as well as signaling functions) may be a common occurrence that may contribute to peripheral mechanisms of hypersensitivity in a number of disorders.

show abstract

Urologic Chronic Pelvic Pain Syndrome

Cited by 6 publications

References 81 publications

Urothelial Signaling

Urothelial Signaling

Therapeutic interventions to urologic chronic pelvic pain syndrome and UPOINT system for clinical phenotyping: How far are we?

Cystitis, Co‐morbid disorders and associated epithelial dysfunction

Contact Info

Product

Resources

About